D57 refers to Sickle-cell disorders, a group of anemias characterized by the destruction of red blood cells (hemolysis) either due to genetic mutations or external/acquired factors. These conditions often require lifelong management and are associated with varying degrees of severity.

Symptoms

Fatigue – Due to decreased oxygen delivery
Jaundice – From bilirubin buildup following red cell breakdown
Dark urine – Indicative of hemoglobinuria
Pallor – From anemia
Enlarged spleen – Common in hemolytic conditions
Delayed growth – Especially in pediatric hereditary cases
Bone deformities – Seen in thalassemia due to marrow expansion

Diagnosis

Diagnosis of Sickle-cell disorders includes complete blood count, reticulocyte count, peripheral smear, bilirubin levels, haptoglobin, LDH, hemoglobin electrophoresis, and genetic or enzymatic assays. Family history and clinical presentation also help differentiate between hereditary and acquired types.

ICD10 Code Usage

ICD10 code D57 is used in hematology and general practice to classify hemolytic anemias for diagnosis, treatment planning, insurance billing, and genetic counseling. It’s critical for monitoring disease progression and treatment efficacy.

Related Codes

FAQs

Q1: What is ICD10 code D57?
A: It refers to Sickle-cell disorders, covering various hemolytic anemias, either inherited or acquired.

Q2: What causes these anemias?
A: Genetic mutations (e.g., G6PD deficiency, sickle cell, thalassemia) or acquired triggers like autoimmune disorders or certain drugs.

Q3: Are these lifelong conditions?
A: Most hereditary types are lifelong. Acquired forms may be temporary or chronic depending on the cause.

Q4: How are they managed?
A: Supportive care, transfusions, iron chelation, immunosuppressants, splenectomy, or bone marrow transplant in severe cases.

Q5: Who is at risk?
A: Individuals with family history or certain ethnic backgrounds (e.g., Mediterranean, African, Southeast Asian) are at higher risk for hereditary forms.

Conclusion

ICD10 code D57 plays an essential role in diagnosing and managing Sickle-cell disorders. It ensures appropriate medical documentation, helps track disease outcomes, and supports access to necessary treatments and follow-up care in patients with hemolytic anemia.